Pulmonx Corp

Universe Pharmaceuticals led Monday's biotech gainers with shares soaring nearly 100% after its SEC filing showed a narrowed net loss for the six months ended March 31, 2026. Revenue was $9.03 million and net loss was $1.55 million, or $2.76 per share, compared with a net loss of $3.28 million, or $9.44 per share, in the year-ago period. Cumberland Pharmaceuticals jumped over 38% ahead of its second-quarter 2026 results due Tuesday, following last month's sale of its branded portfolio to an Apotex Health unit for $100 million in cash. Autolus Therapeutics gained over 22% after reporting preliminary second-quarter AUCATZYL net product revenue of approximately $45 million, up 70% sequentially and more than 100% year over year. Other notable movers included Pulmonx, up over 30% after reaffirming full-year 2026 revenue guidance of $90 million to $92 million, and CAMP4 Therapeutics, which rose over 22% after receiving Australian clearance to begin a Phase 1/2 trial of CMP-002, satisfying a condition to raise up to $50 million in a private placement.

Pulmonx Corporation reported a narrowed net loss and improved gross margin for the second quarter of 2026, sending its stock up over 38%. Revenue fell 5% to $22.8 million, with U.S. revenue down 4% to $14.2 million and international revenue down 6% to $8.6 million, though international sales excluding China grew 12%. Gross margin rose to 78% from 72% a year earlier, while net loss shrank to $10.1 million, or $0.24 per share, from $15.2 million, or $0.38 per share. The company reaffirmed full-year 2026 revenue guidance of $90 million to $92 million and expects gross margin of approximately 76%.